India contributes to over 40% of the global Plasmodium vivax disease burden, and P. vivax contributes to approximately one-third of all malaria in India. Government of India has set goals to eliminate malaria by 2030. Doing so will require scaling up existing and new strategies, treatments and diagnostic tools. Access to appropriate diagnosis and treatment for P. vivax malaria is currently limited, and it is unclear how new tools will be rolled out. To support the government in its malaria elimination efforts, the current challenges associated with access to best clinical management of vivax malaria must be understood and mitigated to effectively deploy new tools and scale up existing solutions. The recent Food and Drug Administration (US-FDA) as well as Therapeutics Goods Administration (Australian TGA) approval of tafenoquine, developed by GSK GlaxoSmithKline and Medicines for Malaria Venture (MMV) as a new single-dose radical cure treatment for P. vivax malaria, and the commercial availability of new point-of-care glucose-6-phosphate dehydrogenase (G6PD) tests provide new opportunities to improve clinical management of vivax malaria in India. This report discusses the background, objectives, implementation strategies, and next steps that came out of the Stakeholder Workshop on Malaria Radical Cure in New Delhi, India on 4 February 2019. The focus was to understand the risks and opportunities associated with access to best clinical practices for managing vivax malaria in India. A key outcome was to propose a framework for articulating and segmenting important investment opportunities for improving access to best clinical practices for P. vivax radical cure in India.

中文翻译：

---

印度疟疾根治机会评估：通过利益相关者召集研讨会讨论机会并建议改善疟疾治疗的可及性

印度占全球间日疟原虫疾病负担的40% 以上，而间日疟原虫占印度所有疟疾的大约三分之一。印度政府制定了到 2030 年消除疟疾的目标。要做到这一点，就需要扩大现有和新的战略、治疗和诊断工具。获得适当的间日疟原虫诊断和治疗疟疾目前有限，尚不清楚将如何推出新工具。为了支持政府消除疟疾的努力，必须了解和缓解与获得间日疟最佳临床管理相关的当前挑战，以有效部署新工具并扩大现有解决方案。最近美国食品和药物管理局 (US-FDA) 以及治疗用品管理局 (澳大利亚 TGA) 批准了由葛兰素史克葛兰素史克和疟疾风险投资公司 (MMV) 开发的他非诺喹作为一种新的单剂量根治性间日疟药疟疾，以及新型床旁葡萄糖 6-磷酸脱氢酶 (G6PD) 测试的商业可用性为改善印度间日疟的临床管理提供了新的机会。本报告讨论了 2019 年 2 月 4 日在印度新德里举行的疟疾根治法利益相关者研讨会的背景、目标、实施策略和后续步骤。重点是了解与获得最佳临床治疗相关的风险和机遇。印度管理间日疟的做法。一个关键成果是提出了一个框架，用于阐明和细分重要的投资机会，以改善印度间日疟原虫根治最佳临床实践的获取途径。